Loading organizations...
§ Public · Richmond, CA, USA
Clinical-stage biotechnology company developing therapeutics to extend healthy lifespan and treat metabolic diseases via AI.
BioAge Labs is a clinical-stage biotechnology company based in Richmond, California, that develops proprietary therapeutics targeting metabolic diseases and the underlying molecular causes of human aging. The organization utilizes an AI-driven discovery platform to analyze longitudinal human health records, advancing a clinical pipeline that includes its lead asset, azelaprag, for the treatment of obesity. Operating with a workforce of approximately 60 employees, the enterprise raised $170 million in an oversubscribed Series D financing round before securing roughly $198 million through its September 2024 initial public offering on the Nasdaq. The firm has established strategic clinical and research partnerships with pharmaceutical corporations like Eli Lilly and Novartis, while receiving equity backing from venture capital investors including Andreessen Horowitz, Khosla Ventures, and Sofinnova Investments. BioAge Labs was founded in 2015 by Kristen Fortney and Eric Morgen.
BioAge Labs has raised $294.0M across 4 funding rounds.
BioAge Labs has raised $294.0M in total across 4 funding rounds.
BioAge Labs has raised $294.0M across 4 funding rounds. Most recently, it raised $170.0M Series D in February 2024.
BioAge Labs has raised $294.0M in total across 4 funding rounds.
BioAge Labs's investors include Sofinnova Investments, F-Prime Capital Partners, Highbury Group, Johnson & Johnson Innovation, Third Rock Ventures, Uprising, VZVC, Amgen Ventures, Bio + Health, Cormorant Asset Management, Lilly Ventures, Patrick Enright.
BioAge Labs is a clinical-stage biotechnology company developing therapies for metabolic diseases like obesity, type 2 diabetes, and cardiovascular disease by targeting the biology of human aging.[1][2][4] Its proprietary human-first platform analyzes over 65 million molecular measurements from 45+ years of longitudinal human data, including omics and health records, to identify novel drug targets for age-related metabolic decline.[1][2][3] The company serves patients with cardiometabolic conditions, addressing unmet needs in an aging population where 988 million live with obesity and 2 billion suffer from related diseases.[1][2]
BioAge's lead program, azelaprag (BGE-102), is an oral APJ agonist entering Phase 2 trials in combination with tirzepatide for obesity in older adults, potentially amplifying weight loss and improving body composition.[2][4] Preclinical programs target additional metabolic aging pathways, with an IND submission anticipated by end-2026 and Phase 1 data for another asset expected in H1 2026.[4] Backed by $491.9 million in funding, BioAge demonstrates strong growth momentum toward IPO.[3][5]
BioAge Labs was co-founded by CEO Kristen Fortney and COO Eric Morgen, with early backing from Pear VC starting in 2015.[5] Fortney, during her postdoc in Professor Stuart Kim’s lab at Stanford Genome Technology Center, studied genetics of extreme human longevity and published extensively on genetics and aging.[5] The idea emerged from her vision to leverage genetic data and machine learning for a therapy discovery platform focused on longevity, initially as a concept before formalizing into BioAge.[5]
Pear VC met Fortney through a mutual founder connection and led the seed round that year, continuing support through Series D.[5] Headquartered in Richmond, CA, the company has evolved from target discovery using human aging cohorts to clinical-stage development, with 51-200 employees and a tech-forward biotech model.[2][5]
BioAge rides the convergence of AI-driven drug discovery, longevity biotech, and the exploding cardiometabolic market, where aging amplifies risks for obesity (988M cases) and related diseases affecting 2B worldwide.[1][4] Timing aligns with GLP-1/incretin booms (e.g., tirzepatide combos) and aging population growth, enabling human-data platforms to outpace traditional animal models.[1][2][5] Market forces like rising metabolic disease prevalence and demand for body composition-focused therapies favor BioAge's apelin/APJ approach, which preclinical data shows doubles weight loss.[2][4]
It influences the ecosystem by validating human longevity cohorts for target ID, inspiring AI-biotech hybrids, and advancing "healthspan" therapies—potentially reshaping obesity treatment beyond weight loss to metabolic aging reversal.[1][5]
BioAge is poised for inflection with azelaprag Phase 2 readouts, a 2026 IND, and Phase 1 data, accelerating its pipeline from human insights to approved therapies.[2][4] Trends like AI-omics integration, combo regimens with incretins, and longevity investing will propel growth toward IPO, as signaled by its trajectory.[3][5] Its influence may expand by pioneering metabolic aging targets, transforming cardiometabolic care for an aging world and validating data-first biotech models.